Association of oestrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer – a retrospective study

BACKGROUND: Oestrogen receptor beta (ERβ) modulates ERα activity; wild type ERβ (ERβ1) and its splice variants may therefore impact on hormone responsiveness of breast cancer. ERβ2/ERβcx acts as a dominant negative inhibitor of ERα and expression of ERβ2 mRNA has been proposed as a candidate marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinayagam, Raman, Sibson, D Ross, Holcombe, Christopher, Aachi, Vijay, Davies, Michael PA
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950511/
https://www.ncbi.nlm.nih.gov/pubmed/17640362
http://dx.doi.org/10.1186/1471-2407-7-131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950511/
https://www.ncbi.nlm.nih.gov/pubmed/17640362
http://dx.doi.org/10.1186/1471-2407-7-131

Ejemplares similares